Physician profile
Steven Harris
NPI 1255393187
$2,802.27
in general payments reported to CMS, 2019-2025
30 companies · $728 in 2025
The $728 reported for 2025 was more than what 84% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $212 · 2020: $113 · 2021: $313 · 2022: $463 · 2023: $453 · 2024: $521 · 2025: $728.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,701.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,700.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $433.84 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Phathom Pharmaceuticals, INC. | $260.37 | 2024-2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $222.51 | 2020-2025 | Eliquis |
| Janssen Pharmaceuticals, INC | $206.49 | 2019-2024 | Xarelto, Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $177.26 | 2019-2023 | Trulance, Xifaxan |
| Glaxosmithkline, LLC. | $172.46 | 2021-2025 | Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $168.02 | 2019-2024 | Tradjenta, Jardiance, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $152.34 | 2022-2025 | |
| Abbvie INC. | $111.91 | 2021-2024 | |
| Amgen INC. | $106.41 | 2019-2023 | Repatha |
| Merck Sharp & Dohme LLC | $95.32 | 2019-2023 | Verquvo, Steglatro, Belsomra |
| Nevro Corp. | $86.39 | 2022-2024 | Senza |
| Exact Sciences Corporation | $70.74 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Novo Nordisk INC | $63.58 | 2022-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $58.12 | 2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $57.24 | 2021-2023 | Livalo, Seglentis |
| Seqirus USA INC | $50.92 | 2025 | Flucelvax |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.79 | 2024-2025 | Caplyta |
| Xeris Pharmaceuticals, INC. | $42.64 | 2023-2024 | Keveyis, Gvoke Hypopen |
| Otsuka America Pharmaceutical, INC. | $41.89 | 2025 | Rexulti |
| Sanofi Pasteur INC. | $33.50 | 2023-2025 | |
| Lundbeck LLC | $22.39 | 2024 | Rexulti |
| Regeneron Healthcare Solutions, INC. | $17.75 | 2021 | |
| Scilex Pharmaceuticals INC. | $17.71 | 2022 | |
| Novartis Pharmaceuticals Corporation | $17.27 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $15.47 | 2021 | |
| Arbor Pharmaceuticals, INC. | $14.71 | 2019 | |
| Sumitomo Pharma America, INC. | $14.42 | 2025 | Gemtesa |
| Idorsia Pharmaceuticals US INC | $12.66 | 2022 | |
| Almatica Pharma LLC | $11.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.